The move comes as the company’s Chairman Heo Seung Beom increases his shareholding to support the company’s third-generation leadership transition.

Established in 1947, Samil Pharmaceutical is widely known in the Republic of Korea for its children’s antipyretic medicine Brupen. It also manufactures and markets pharmaceuticals and nutraceuticals including Libact, Foributin and Monoprost.

Under its strategic shift, the company is increasingly focusing on overseas production. In 2022, Samil Pharmaceutical completed a contract development and manufacturing organisation (CDMO) facility in Vietnam specialising in ophthalmic products.

The plant spans about 24,800 square metres and has an annual production capacity of 330 million eye-drop units.

The company aims to take advantage of lower labour costs in Vietnam to strengthen its price competitiveness. However, the facility has not yet entered full-scale commercial production, as it awaits Good Manufacturing Practice (GMP) approvals in key target markets.

Following GMP certification from Vietnamese authorities in 2024, Samil Pharmaceutical is now seeking approval from the RoK’s Ministry of Food and Drug Safety in the second half of this year. The company said the approval process is expected to take around two to three months.

Vietnam's pharmaceutical market sees major M&A deal

The Vietnamese pharmaceutical sector has recently witnessed one of its largest mergers and acquisitions (M&A) to date, with Livzon Pharmaceutical Group Inc. of China acquiring approximately 64.81% of Imexpharm Pharmaceutical Joint Stock Company (IMP).